Clinical Trials Logo

Glucose Tolerance Impaired clinical trials

View clinical trials related to Glucose Tolerance Impaired.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT05093517 Suspended - Type 2 Diabetes Clinical Trials

Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM

Start date: November 10, 2021
Phase: Early Phase 1
Study type: Interventional

With REMD's glucagon receptor antagonist, the study team propose to provide a comprehensive examination of the effect of elevated plasma glucagon concentrations in Type 2 Diabetes Mellitus (T2D) patients on: (i) glucose tolerance; (ii) insulin sensitivity in liver, muscle, and adipocytes; (iii) beta cell function; (iv) adipocyte inflammation.